Survival analysis of small cell carcinomas of the genitourinary system.
| Autor: | Baralo B; Internal Medicine, Mercy Catholic Medical Center, Darby, Pennsylvania., Schneider M; Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Baralo I; Urology, National Pirogov Memorial Medical University, Vinnytsia, Ukraine. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Proceedings (Baylor University. Medical Center) [Proc (Bayl Univ Med Cent)] 2022 Oct 14; Vol. 36 (1), pp. 8-14. Date of Electronic Publication: 2022 Oct 14 (Print Publication: 2023). |
| DOI: | 10.1080/08998280.2022.2123664 |
| Abstrakt: | Due to low incidence, there are no large prospective studies or clinical trials for small cell carcinoma (SCC) of the genitourinary system (GU), and most data are extrapolated from SCC of the lung. Using the SEER database, we analyzed incidence trends, overall survival, and cancer-specific survival using the log-rank test. Analysis of variables was performed using the Cox proportional hazards regression model. The analysis showed that SCC of the bladder and prostate were the most common types of GU SCC, with 1836 and 606 cases, respectively. In 2018, the incidence of SCC of the bladder and prostate was twice that of 2010 ( P < 0.001). The overall survival and cancer-specific survival of patients with SCC of the bladder were significantly longer than those of patients with SCC of the prostate ( P < 0.0001). SCC bladder patients with advanced age, more extensive growth, lymph node involvement, no surgical intervention, and the presence of the metastasis had worse survival outcomes ( P < 0.05). The Asian/Pacific Islander race provided some survival benefits for patients with SCC of the bladder ( P < 0.05). For patients with SCC of the prostate, only advanced age was a risk factor for poor outcomes ( P < 0.05). (Copyright © 2022 Baylor University Medical Center.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|